BIN1 is a novel MYC-interacting protein with features of a tumour suppressor

Nature Genetics

Volumn 14, Issue 1, 1996, Pages 69-77

  Sakamuro, Daitoku ^a   Elliott, Katherine J ^a   Wechsler Reya, Robert ^a   Prendergast, George C ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CELL STRUCTURE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CARRIER PROTEINS; CELL DIVISION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA PRIMERS; FUNGAL PROTEINS; GENES, MYC; GENES, TUMOR SUPPRESSOR; HELA CELLS; HUMANS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; TRANSFORMATION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0029741917     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng0996-69     Document Type: Article

References (63)

1. Cole, M.D. The myc oncogene: Its rote in transformation and differentiation. Annu. Rev. Genet. 20, 361-384 (1986).
2. Evan, G.I. & LJttlewood, T.D. The role of c-myc in cell growth. Curr. Opin. Genet. Dev. 3, 44-49 (1993).
3. Packham, G. & Cleveland, J. c-Myc and apoptosis. Biochim. Biophys. Xicta1242, 11-28(1995).
4. Henriksson, M. & Lüscher, B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. 68, 109-182(1996).
5. Eilers, M., Picard, D., Yamamoto, K.R. & Bishop, J.M. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Mature 340, 66-8 (1989).
6. Heikkila, R. et al. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from GO to G1. Nature 328, 445-448 (1987).
7. Holt, J.T., Redner, R.L & Nienhuis, A.W. An oligomer complementary to c-myc mRNA inhibits prolieration of HL-60 promyelootio cells and induces differentiation. Mol. Cell. Biol. 8.963-973 (1988).
8. Sklar, M.D. et al. Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells.mol. Cell. Biol. 11, 3699-3710(1991).
9. Sawyers, C.L, Callahan, W. & Witte, O.N. Dominant negative MYC blocks transformation by ABLoncogenes. Ce//70, 901-10 (1992).
10. Hanson, K.D., Shichiri, M., Follansbee, M.R. & Sedivy, J.M. Effects of cmyc expression on cell cycle progression. Mol. Cell. Biol. 14, 5748-5755 (1994).
11. Askew. D.S., Ashmun, R.A., Simmons, B.C. & Cleveland, J.L Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6, 1915-22(1991).
12. Evan, G.I. et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69.119-128 (1992).
13. Meichle, A., Philipp, A. & Eilers, M. The functions of Myc proteins. Biochim Biophys Acta 1114, 129-46(1992).
14. Stone, J. eraJ. Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol. Cell. Biol. 7, 1697-1709 (1987).
15. Kato, G.J., Barrett, J., Villa-Garcia, M. & Dang, C.V. An amino-terminal cMyc domain required for neoplastic transformation activates transcription. Mol. Cell. Biol. 10, 5914-5920 (1990).
16. Gupta, S., Seth, A. & Davis, R.J. Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62. Proc. NatJ. Acad. Sci. USA 90, 3216-3220 (1993).
17. Seth, A., Gupta, S. & Davis, R.J. Cell cycle regulation of the c-Myc transcriptional activation domain. mol. Ce/J. B/oJ. 13, 4125-4136(1993).
18. Lutterbach, B. & Hann, S.R. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol. Cell. Biol. 14, 5510-5522 (1994).
19. Hoang, AT. et al. A link between increase transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol. Cell. Biol. 15, 4031-4042 (1995).
20. U, L, Nerlov, C., Prendergast, G., MacGregor, D. & Ziff, E.B. c-Myc activates and represses target gene through the E-box Myc binding site and the core promoter region respectively. EMBO J. 13, 4070-4079 (1994).
21. Papas, T.S. & Lautenberger, J.A. Sequence curiosity in v-myc oncogene. Nafure318, 237 (1985).
22. Bhatia, K. et al. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nature Genet. 5, 56-61 (1993).
23. Yano, T. et al. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Oncogene 8, 2741 -8 (1993).
24. Gu, W., Bhatia, K., Magrath, IT., Dang, C.V. & DallaFavera, R. Binding and suppresion of the myc transcriptional activation domain by p107. Science 264, 251-254 (1994).
25. Beijersbergen, R.L, Hijmans, E.M., Zhu, L & Bernards, R. Interaction of c-Myc with the pRb-related protein p107 results in inhibition of c-Mycmediated transactivation. EMBO J. 13, 408CM086 (1994).
26. Vojtek, A.B., Hollenberg, S.M. & Cooper, JA Mammalian ras interacts directly with the serine/threonine kinase Raf. Cell 74, 205-214 (1993).
27. Pulverer, B.J. et al. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9, 59-70 (1994).
28. Bianchi, M.W., Plyte, S.E., Kreis. M. & Woodgett, J.R. A Saccharomyces cerevisiae protein-serine kinase related to mammalian glycogen synthase kinase-3 and the Drosophila melanogaster gene shaggy product. Gene 134, 51-6 (1993).
29. Pawson, T. & Gish, G.D. SH2 and SH3 domains: from structure to function. Ce 71, 359-362 (1992).
30. Uchte, B., Veh, R.W., Meyer, H.E. & Kilimann. M.W. Amphiphysin, a novel protein associated with synaptic vesicles. EMBO J. 11, 2521-2530(1992).
31. Folli, F. etal. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. W. Engl. J. /Wed. 328, 546-51 (1993).
32. Brown, R.H. in Principles of Internal Medicine (eds Isselbacher. K.J.) 1878-1882 (McGraw-Hill, New York, 1994).
33. Bauer, F., Urdaci, M., Aigle, M. &. Crouzet, M. Alteration of a yeast SH3 protein leads to conditional viability with defects in cytoskeletal and budding patterns. Mol. Cell. Biol. 13, 5070-5084 (1993).
34. Land, H., Parada, LF. & Weinberg, RA Tumorigenic conversion of primary embryo fibrablasts requires at least two cooperating oncogenes. Nature 304, 596-602 (1983).
35. Ruley, H.E. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 304, 602-606(1983).
36. Rao, L et al. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc. WatJ. Acad. Sci. USA 89, 7742-7746 (1992).
37. Leder, A., Pattengale, P.K., Kuo, A., Stewart, TA & Leder, R Consequences of widespread deregulation of the c-myc gene in transgenio mice: multiple neoplasms and normal development. Cell 45, 485-95(1986).
38. Sinn, E. et al. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49, 465-75(1987).
39. Berns, E.M. et al. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 52, 1107-13(1992).
40. Hehir, D.J., McGreal, G., Kirwan, W.O., Kealy, W. & Brady, M.P. c-myc oncogene expression: a marker for females at risk of breast carcinoma. J. Surg. Oncol. 54.207-9 (1993).
41. Kreipe, H. et al. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res. 53, 1956-61 (1993).
42. Watson, P.M., Safneck, J.R., Le, K., Dubik. D. & Shiu, R.R Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J. WatJ. Cancer Inst 85, 902-7(1993).
43. David, C., McPherson, P.S., Mundigl, O. & de Camilli, P. A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. Proc. WatJ. Acad. Sci. USA 93, 331-335 (1996).
44. Gaubatz, S., Meichle, A. & Eilers, M. An E-box element localized in the first intron mediates regulation of the prothymosin a gene by c-myc. Mol. Cell. BibJ. 14, 3853-3862 (1994).
45. Born, T., Frost, J., Schanthal, A., Prendergast, G.G. & Feramisco, J. cMyc and oncogenic ras induce the cdc2 promoter. Mol. Cell. Biol. 14, 5741-5747(1994).
46. Bello-Fernandez, C., Packham, G. & Cleveland, J.L The ornithine decarboxylase gene is a transcriptional target of c-MYC. Proc. Watt Acad. Sci. USA 90, 7804-7803 (1993).
47. Sakamuro, D. et al. c-Myc induces apoptosis in epithelial cells by p53dependent and p53-independent mechanisms. Oncogene 11, 2411-2418(1995).
48. Negorev, D. et al. The Bin1 gene localizes to human chromsome 2q14 by PCR analysis of somatic cell hybrids and fluorescence in situ hybridization. Genomics 33, 329-331 (1996).
49. Cher, M.L. et al. Genetic alterations in untreated métastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 56, 3091-3102 (1996).
50. Hayata, I. et al. Chromosomal aberrations observed in 52 mouse myeloid leukemias. Cancer Res. 43, 367-373 (1983).
51. Jahner, D. & Hunter, T. The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts. Mol. Cell. Biol. 11, 3682-3690 (1991).
52. Murre, C., McCaw, P.S. & Baltimore, D. A new DMA-binding and dimerization motif in immunoglobulin enhancer binding, daughter-less, MyoD, and Myc proteins. Cell 56, 777-783 (1989).
53. Prendergast, G.C., Lawe, D. & Ziff, E.B. Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and Ras cotransformation. Cell 65, 395-407 (1991).
54. Niman, H.L et al. Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition. Proc. WatJ. Acad. Sci. USA 80, 4949-4953 (1983).
55. Kelekar, A. & Cole, M. Tumorigenicity of fibroblast lines expressing the adenovirus E1a, cellular p53, or normal c-myc genes. Mol. Cell. Biol. 6, 7-14(1986).
56. Prendergast, G.G., Hopewell. R., Gorham. B. & Ziff, E.B. Biphasic effect of Max on Myc transformation activity and dependence on N- and Cterminal Max functions. Genes Dev. 6, 2429-2439 (1992).
57. Chen, C. & Okayama, H. High efficiency transformation of mammalian cells by plasmid DNA. Moi. Cell. Biol. 7, 2745-2752 (1987).
58. Hartow, E. & Lane, D. Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1988).
59. Prendergast, G.C. & Ziff, E.B. Mbh1: A novel gelsolin/severin-related protein which binds actin in vitro and exhibits nuclear localization in vivo. EMBOJ. 10, 757-766(1991).
60. Prendergast, G.C. & Cole, M.D. Posttranscriptional regulation of cellular gene expression by the c-myc oncogene. Mol. Cell. Biol. 9, 124-134 (1989).
61. Shiozawa, M. et al. Synthesis of human gamma-glutamyl transpeptidase (GGT) during the fetal development of liver. Gene 87, 299-303(1990).
62. Church, G.M. & Gilbert, W. Genomic sequencing. Proc. WalJ. Acad. Sci. USA 81, 1991-1995 (1984).
63. Yamamoto, R., Li, X., Winter, S., Francke, U. & Kilimann, M.W. Primary structure of human amphiphysin, the dominant autoantigen of paraneoplastic Stiff-Man Syndrome, and mapping of its gene (AMPH) to chromosome 7p13-p14. Human Mol. Genet. 4, 265-268 (1995).